Abbott Laboratories (ABT) New York Stock Exchange
CloseMay 21, 2019

News: updated – 22-May 02:08

Abbott’s tricuspid valve repair device shows positive effect in study21-May 11:59(SeekingAlpha)

Results from a study called TRILUMINATE evaluating Abbott’s ( ABT +0.7% ) minimally invasive tricuspid valve repair system in 85 patients with symptomatic moderate (or greater) tricuspid regurgitation (TR)showed a treatment benefit. The data were presented at EuroPCR in Par…

TRILUMINATE Study Shows Treatment with Abbott’s First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks21-May 10:45(PR Newswire)

PARIS , May 21, 2019 /PRNewswire/ –Abbott (NYSE: ABT) today announced positive late-breaking data from its TRILUMINATE study of the company’s minimally invasive tricuspid valve repair system. Results at 30 days demonstrated that the investigational device is associated with a reduc…